many here have read about research trying to determine if taking PPIs reduces risk of esophageal cancer
weve read some findings indicating PPI usage may be associated with increased risk but its not clear if this relationship is associational,,,or,,, is causal as some doctors propose
weve been looking for similar studies regarding H2s (famotidine, ranitidine etc)
here it is...or was, the study was done a decade ago at fred hutch in seattle
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer.
Farrow DC, Vaughan TL, Sweeney C, Gammon MD, Chow WH, Risch HA, Stanford JL, Hansten PD, Mayne ST, Schoenberg JB, Rotterdam H, Ahsan H, West AB, Dubrow R, Fraumeni JF Jr, Blot WJ.
Fred Hutchinson Cancer Research Center, and University of Washington, School of Public Health & Community Medicine, Department of Epidemiology, Seattle 98109-1024, USA. firstname.lastname@example.org
The incidence of esophageal adenocarcinoma has risen rapidly in the past two decades, for unknown reasons. The goal of this analysis was to determine whether gastroesophageal reflux disease (GERD) or the medications used to treat it are associated with an increased risk of esophageal or gastric cancer, using data from a large population-based case-control study.
Cases were aged 30-79 years, newly diagnosed with esophageal adenocarcinoma (n = 293), esophageal squamous cell carcinoma (n = 221), gastric cardia adenocarcinoma (n = 261), or non-cardia gastric adenocarcinoma (n = 368) in three areas with population-based tumor registries. Controls (n = 695) were chosen by random digit dialing and from Health Care Financing Administration rosters. Data were collected using an in-person structured interview.
History of gastric ulcer was associated with an increased risk of non-cardia gastric adenocarcinoma (OR 2.1, 95% CI 1.4-3.2). Risk of esophageal adenocarcinoma increased with frequency of GERD symptoms; the odds ratio in those reporting daily symptoms was 5.5 (95% CI 3.2-9.3).
**Ever having used H2 blockers was unassociated with esophageal adenocarcinoma risk** (OR 0.9, 95% CI 0.5-1.5). The odds ratio was 1.3 (95% CI 0.6-2.8) in long-term (4 or more years) users, but increased to 2.1 (95% CI 0.8-5.6) when use in the 5 years prior to the interview was disregarded. Risk was also modestly increased among users of antacids. Neither GERD symptoms nor use of H2 blockers or antacids was associated with risk of the other three tumor types. (my emphasis added)
Individuals with long-standing GERD are at increased risk of esophageal adenocarcinoma, whether or not the symptoms are treated with H2 blockers or antacids.
PMID: 10782657 [PubMed - indexed for MEDLINE]